2024

• Tan, L., Brown, C., Mersiades, T., Lee, C., John, T., Kao, S., Newnham, G., O'Byrne, K., Parakh, S., Bray, V., Yip, S., Clarke, S., Pavlakis, N., Stockler, M., et al (2024). A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE. Nature Communications, 15(1). [More Information]
• Mersiades, T., Solomon, B., Thomas, D., Lee, C., Parry, M., Sebastian, L., Ballinger, M., Collignon, E., Turnbull, O., Yip, S., Morton, R., Brown, C., Itchins, M., Simes, R., Pavlakis, N., et al (2024). ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue. Future Oncology, 20(7), 361-371. [More Information]
• Werner, B., Sjoquist, K., Espinoza, D., Yip, S., Chang, G., Parry, M., Mileshkin, L., Ananda, S., Shannon, C., Friedlander, M., et al (2024). Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial. Translational Oncology, 43. [More Information]
• Sharifi, N., Portman, N., Davis, I., Sweeney, C., Diaz, R., Lin, H., Roberts, E., Horvath, L., Martin, A., Stockler, M., Yip, S., et al (2024). Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance. Journal of Clinical Investigation, 134(18), e183583. [More Information]

2023

• Hao, Y., Miraghazadeh, B., Chand, R., Davies, A., Cardinez, C., Kwong, K., Downes, M., Sweet, R., Cañete, P., D’Orsogna, L., Yip, S., et al (2023). CTLA4 protects against maladaptive cytotoxicity during the differentiation of effector and follicular CD4+ T cells. Cellular & Molecular Immunology, 20(7), 777-793. [More Information]
• Lam, L., Pavlakis, N., Shitara, K., Sjoquist, K., Martin, A., Yip, S., Kang, Y., Bang, Y., Chen, L., Moehler, M., Hague, W., Gebski, V., Jaworski, A., Simes, R., et al (2023). INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG). BMC Cancer, 23(1). [More Information]
• Sim, H., Wachsmuth, L., Barnes, E., Yip, S., Koh, E., Hall, M., Jennens, R., Kong, B., Simes, R., Khasraw, M., et al (2023). NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma. Neuro-Oncology Advances, 5(1), vdad124. [More Information]
• Smith, D., Robledo, K., Yip, S., Parry, M., Kok, P., Lee, C., Friedlander, M., Baron-Hay, S., Shannon, C., Coward, J., Andrews, J., Stockler, M., et al (2023). Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). Cancers, 15(1). [More Information]
• Sweeney, C., Martin, A., Stockler, M., Begbie, S., Cheung, L., Chi, K., Chowdhury, S., Frydenberg, M., Horvath, L., Joshua, A., Winter, D., Yip, S., Zhang, A., et al (2023). Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. The Lancet Oncology, 24(4), 323-334. [More Information]

2022

• Stockler, M., Martin, A., Davis, I., Dhillon, H., Begbie, S., Chi, K., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W., Winter, D., Yip, S., et al (2022). Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. Journal of Clinical Oncology, 40(8), 837-846. [More Information]
• Kong, B., Sim, H., Barnes, E., Nowak, A., Hovey, E., Jeffree, R., Harrup, R., Parkinson, J., Gan, H., Pinkham, M., Yip, S., Hall, M., Tu, E., Carter, C., Simes, R., et al (2022). Multi-Arm GlioblastoMa Australasia (MAGMA): Protocol for a multiarm randomised clinical trial for people affected by glioblastoma. BMJ Open, 12(9). [More Information]
• Kok, P., Forde, P., Hughes, B., Sun, Z., Brown, C., Ramalingam, S., Cook, A., Lesterhuis, W., Yip, S., O'Byrne, K., Pavlakis, N., Ford, K., Parry, M., Stockler, M., et al (2022). Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial. BMJ Open, 12(1), e057663-1-e057663-8. [More Information]

2021

• Mitchell, P., O'Byrne, K., Stockler, M., Yip, S., nhmrWalker, M., Balasubramaniam, S., Ab Rahman, A., Kok, P., Jurkovic, H., Brown, C., et al (2021). A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD). International Journal of Radiation Oncology Biology Physics, 111(3), S10-S11. [More Information]
• Sim, H., McDonald, K., Lwin, Z., Barnes, E., Rosenthal, M., Foote, M., Koh, E., Back, M., Wheeler, H., Sulman, E., Buckland, M., Fisher, L., Leonard, R., Hall, M., Yip, S., Simes, R., Khasraw, M., et al (2021). A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: The VERTU study. Neuro-Oncology, 23(10), 1736-1749. [More Information]
• Oar, A., Lee, M., Le, H., Wilson, K., Aiken, C., Chantrill, L., Simes, R., Nguyen, N., Barbour, A., Samra, J., Sjoquist, K., Espinoza, D., Gebski, V., Yip, S., Kneebone, A., Goldstein, D., et al (2021). AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer, 21(1), 936. [More Information]
• Antill, Y., Kok, P., Robledo, K., Yip, S., Parry, M., Smith, D., Spurdle, A., Barnes, E., Lee, C., Friedlander, M., Andrews, J., Stockler, M., et al (2021). Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. Journal for ImmunoTherapy of Cancer, 9(6), 2255. [More Information]
• Emmett, L., Balasubramaniam, S., Joshua, A., Crumbaker, M., Martin, A., Zhang, A., Rana, N., Langford, A., Mitchell, J., Yip, S., Stockler, M., et al (2021). ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU International, 128(5), 642-651. [More Information]
• Kong, B., Sim, H., Nowak, A., Yip, S., Barnes, E., Day, B., Buckland, M., Verhaak, R., Johns, T., Robinson, C., Hall, M., Tu, E., et al (2021). LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study. BMJ Open, 11(12), e054075. [More Information]
• Siu, D., Tebbutt, N., Chantrill, L., Karapetis, C., Steer, C., Wilson, K., Espinoza, D., Bailey, L., Yip, S., Cuff, J., Pavlakis, N., Thavaneswaran, S., Shannon, J., Segelov, E., Price, T., Sjoquist, K., et al (2021). MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). BMC Cancer, 21(1), 932. [More Information]
• Sweeney, C., Martin, A., Stockler, M., Begbie, S., Chi, K., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W., Horvath, L., Joshua, A., Marx, G., McJannett, M., Tu, E., Yip, S., Zhang, A., et al (2021). Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 80(3), 275-279. [More Information]
• Sjoquist, K., Espinoza, D., Mileshkin, L., Ananda, S., Shannon, C., Yip, S., Goh, J., Bowtell, D., Harrison, M., Friedlander, M. (2021). REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. Gynecologic Oncology, 161(2), 374-381. [More Information]

2020

• Nowak, A., Lesterhuis, W., Kok, P., Brown, C., Hughes, B., Karikios, D., John, T., Kao, S., Leslie, C., Cook, A., Langford, A., Yip, S., Stockler, M., et al (2020). Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. The Lancet Oncology, 21(9), 1213-1223. [More Information]

2019

• Yip, S., Fleming, J., Shepherd, H., Walczak, A., Clark, J., Butow, P. (2019). "As Long as You Ask": A Qualitative Study of Biobanking Consent-Oncology Patients' and Health Care Professionals' Attitudes, Motivations, and Experiences-the B-PPAE Study. The Oncologist, 24(6), 844-856. [More Information]
• Tang, M., Joensuu, H., Simes, R., Price, T., Yip, S., Hague, W., Sjoquist, K., Zalcberg, J. (2019). Challenges of international oncology trial collaboration-a call to action. British Journal of Cancer, 121(7), 515-521. [More Information]
• Davis, I., Martin, A., Stockler, M., Begbie, S., Chi, K., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W., Horvath, L., Marx, G., Tu, E., Yip, S., Zhang, A., et al (2019). Enzalutamide with standard first-line therapy in metastatic prostate cancer. New England Journal of Medicine, 381(2), 121-131. [More Information]
• Olafson, L., Siddell, A., Field, K., Byrnes, M., Rapkins, R., Ng, B., Nixdorf, S., Barnes, E., Johns, T., Yip, S., Simes, R., et al (2019). Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial. Journal of Clinical Neuroscience, 70, 157-163. [More Information]

2018

• Lawrence, N., Chan, H., Toner, G., Stockler, M., Martin, A., Yip, S., Wong, N., Yeung, A., Mazhar, D., Pashankar, F., et al (2018). Protocol for the P3BEP trial (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours. BMC Cancer, 18(1), 1-6. [More Information]

2016

• Pavlakis, N., Sjoquist, K., Martin, A., Tsobanis, E., Yip, S., Kang, Y., Bang, Y., Alcindor, T., O'Callaghan, C., Burnell, M., Wong, K., Simes, R., et al (2016). Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II Trial. Journal of Clinical Oncology, 34(23), 2728-2735. [More Information]

2015

• Davis, I., Long, A., Yip, S., Espinoza, D., Thompson, J., Kichenadasse, G., Harrision, M., Lowenthal, R., Pavlakis, N., Azad, A., Hudson, A., Stockler, M., Martin, A., et al (2015). EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma. Annals of Oncology, 26(6), 1118-1123. [More Information]
• Chantrill, L., Nagrial, A., Watson, C., Johns, A., Martyn-Smith, M., Simpson, S., Mead, S., Jones, M., Samra, J., Gill, A., Chin, V., Sebastian, L., Sjoquist, K., Yip, S., Pavlakis, N., Grimison, P., Simes, R., et al (2015). Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clinical Cancer Research, 21(9), 2029-2037. [More Information]

2011

• Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]
• Yip, S. (2011). Translational research and personalised medicine. The Australian New Zealand Gynaecological Oncology Group (ANZGOG) ASM.

2010

• Karapetis, C., Cheong, K., Yip, D., Strickland, A., Steer, C., Marx, G., Yip, S., Chrystal, K., Harper, P. (2010). A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas. Asia-Pacific Journal of Clinical Oncology, 6(4), 289-305. [More Information]